HYPERTHYROIDISM SECONDARY TO GESTATIONAL TROPHOBLASTIC DISEASE: A LITERATURE REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i6.1706Keywords:
β-hCG, Gestational trophoblastic disease, HyperthyroidismAbstract
Gestational trophoblastic disease (GTD) is a rare form of pregnancy-related cancer that is effectively treatable. GTD is accompanied by the potentially fatal complication of hyperthyroidism. We created a review consisting of five case reports. This case report was conducted on women who became pregnant when they were >35 years old. They showed consistent laboratory results, in which there was an increase in hCG levels. TSH and thyroid stimulating antibodies cannot account for the hyperthyroidism associated with GTD. The source of the thyroid stimulating agent is trophoblastic tissue. The thyrotropic effects of β-hCG mediate GTD hyperthyroidism. Other research examined the prevalence of hyperthyroidism in women with normal pregnancy, hydatidiform mole, and choriocarcinoma who had β-hCG serum levels below 100,000 IU/ml. Early prenatal screening may significantly reduce hyperthyroidism rates. Thyroid hormone synthesis inhibitors treat hyperthyroidism in pregnancy. Thioamides, propylthiouracil (PTU), and methimazole (MMI) are the most prevalent U.S. antithyroid medications (ATD). Plasmaphoresis may be an option for people who are resistant to therapy or need emergency surgery. GTD can cause fatal hyperthyroidism. Anti-thyroid medicines can handle most GTD hyperthyroidism. Surgery may be a possibility for patients refractory to medical treatment.
References
Cunningham FG; et al, Cunningham FG; Leveno KJ; Bloom SL; et al, F. Gary Cunningham, Kenneth J. Leveno, Steven L. Bloom, Catherine Y. Spong, Jodi S. Dashe BLH. Williams Obstetri. 25th ed. New York: The McGrawHill Companies; 2020.
Anand SSV, Bhaskaran M, Rakshith UR. Gestation trophoblastic disease--A comprehensive review. Drug Invent Today. 2020;13(1).
Kaur B. Pathology of gestational trophoblastic disease (GTD). Best Pract Res Clin Obstet Gynaecol. 2021 Jul;74:3– 28.
Lurain J, Seckl M, Schink J. Gestational trophoblastic disease. Textb Uncommon Cancer. 2017;653–62.
Brown J, Naumann RW, Seckl MJ, Schink J. 15 years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage. Gynecol Oncol. 2017;144(1):200–7.
Soper JT. Gestational Trophoblastic Disease: Current Evaluation and Management. Obstet Gynecol. 2021 Feb;137(2):355–70.
Shaaban AM, Rezvani M, Haroun RR, Kennedy AM, Elsayes KM, Olpin JD, et al. Gestational Trophoblastic Disease: Clinical and Imaging Features. Radiogr a Rev Publ Radiol Soc North Am Inc. 2017;37(2):681–700.
Pereira JV-B, Lim T. Hyperthyroidism in gestational trophoblastic disease – a literature review. Thyroid Res [Internet] 2021;14(1):1. Available from: https://doi.org/10.1186/s13044-021-00092-3
Padmanabhan LD, Mhaskar R, Mhaskar A, Vallikad E. Trophoblastic hyperthyroidism. J Assoc Physicians India. 2003 Oct;51:1011–3.
Paulo R, Matlock K, Bowlby D. ODP390 Metastatic Gestational Trophoblastic Neoplasia Masquerading as Thyroid Storm in a Girl with Molar Pregnancy and Hyperthyroidism. J Endocr Soc. 2022;6(Supplement_1):A604–5.
Rahmadhona D, Tambunan BA. Gestational Trophoblastic Neoplasia with Hyperthyroidism. Chemotherapy. 2020;1:2.
Düğeroğlu H, Özgenoğlu M. Thyroid function among women with gestational trophoblastic diseases. A crosssectional study. Sao Paulo Med J. 2019;137:278–83.
Grzechocinska B, Gajewska M, Kedzierski M, Gajda S, Jedrzejak P, Wielgos M. Hyperthyroidism secondary to a hydatidiform mole. Ginekol Pol. 2021;92(10):741–2.
Chale-Matsau B, Mokoena S, Kemp T, Pillay TS. Hyperthyroidism in molar pregnancy: β-HCG levels do not always reflect severity. Clin Chim Acta. 2020 Dec;511:24–7.
De Guzman E, Shakeel H, Jain R. Thyrotoxicosis: a rare presentation of molar pregnancy. BMJ Case Rep. 2021 Jul;14(7).
Da Silva Santos T, Santos Monteiro S, Pereira MT, Garrido S, Leal M, Andrade C, et al. Severe Hyperthyroidism and Complete Hydatidiform Mole in Perimenopausal Woman: Case Report and Literature Review. Vol. 14, Cureus. United States; 2022. p. e22240.
Simes BC, Mbanaso AA, Zapata CA, Okoroji CM. Hyperthyroidism in a complete molar pregnancy with a mature cystic ovarian teratoma. Vol. 11, Thyroid research. England; 2018. p. 12.
Walkington L, Webster J, Hancock BW, Everard J, Coleman RE. Hyperthyroidism and human chorionic gonadotrophin production in gestational trophoblastic disease. Br J Cancer. 2011;104(11):1665–9.
Sun SY, Melamed A, Joseph NT, Gockley AA, Goldstein DP, Bernstein MR, et al. Clinical presentation of complete hydatidiform mole and partial hydatidiform mole at a regional trophoblastic disease center in the United States over the past 2 decades. Int J Gynecol Cancer. 2016;26(2).
Bahasadri S, Kashanian M. Clinical presentation of molar pregnancy at a teaching hospital in Iran, 1996-2006. Int J Gynaecol Obstet. 2011;115(2):194–5.
Earl R, Crowther CA, Middleton P. Interventions for hyperthyroidism pre-pregnancy and during pregnancy. Cochrane database Syst Rev. 2013 Nov;(11):CD008633.
Moleti M, Di Mauro M, Sturniolo G, Russo M, Vermiglio F. Hyperthyroidism in the pregnant woman: Maternal and fetal aspects. J Clin Transl Endocrinol. 2019 Jun;16:100190.
Kobaly K, Mandel SJ. Hyperthyroidism and Pregnancy. Endocrinol Metab Clin North Am. 2019 Sep;48(3):533–45.
Illouz F, Luton D, Polak M, Besançon A, Bournaud C. Graves’ disease and pregnancy. Ann Endocrinol (Paris). 2018 Dec;79(6):636–46.
King JR, Lachica R, Lee RH, Montoro M, Mestman J. Diagnosis and Management of Hyperthyroidism in Pregnancy: A Review. Obstet Gynecol Surv. 2016 Nov;71(11):675–85.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
